Comparative effectiveness of infliximab and adalimumab for Crohn's disease. - Wikidata - awgldk - TriplyDB

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

http://www.wikidata.org/entity/Q37445629

about

Structural and molecular features of intestinal strictures in rats with Crohn's-like disease Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments.Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study.Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease Cytokine networking of innate immunity cells: a potential target of therapy.Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.An update on medical management on Crohn's disease.Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.Update on the Medical Management of Crohn's Disease.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.Essential Medicines List Implementation Dynamics: A Case Study Using Brazilian Federal Medicines Expenditures.Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development.Top-down Versus Step-up Prescribing Strategies for Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease.Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease.Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab.What is the need for comparative effectiveness studies in IBD?Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy.Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?

P2860

Q24658466-062C59EA-39D0-4921-AE25-91D318607D44 Q30239737-F22FB178-DC6E-4BFA-8BC8-5F459422A6E2 Q33606172-735EFE3C-FDBF-44DB-AC05-98B1A7D6B5EF Q33641909-AF5EF3E2-0486-45DC-A303-DC7DF3741895 Q35763489-B35EAE90-9522-43E8-8698-BEBFE9389EE1 Q35773115-5574D7BF-649C-4729-97D7-C5AD24C5F75E Q36689512-5D05D0C5-5B29-47CA-BEF8-7F9EFB8AE6C1 Q36882311-288AE29C-E84D-48B5-8DE4-94DCBA5C0D63 Q37029359-AB6C0C14-BAC8-4A94-B238-83BDCFB3C071 Q37047522-6D2484A9-135B-4722-951E-221BA89A6C36 Q37719806-A6782CF2-9794-4178-BF0A-E599C13E9C98 Q38180799-BBE4D2AA-33A1-4CA5-BBB1-4E4F7C59B3AB Q38186069-443BFB7F-FA4C-4E26-9871-65E6F35B5366 Q38205873-0485DDE6-522D-4FB3-9F66-37B0E81764C8 Q38270674-311E26B6-D87D-4FDE-A8A6-C071EC6114EC Q38549995-4D0C9962-078E-4554-BEA7-97B96004AD0E Q38585634-D2C9F2C8-C926-4066-B630-0C9108BA790F Q38630959-3BF13FFF-FFB8-461B-93A5-163D2AB5A879 Q38858834-E0D4E5FB-362F-46C1-A0F9-1C999420EEA7 Q38883385-085AA6D1-F0C1-465B-9231-C63BE4CB2397 Q39012932-000ED87E-FCB8-4330-9B77-A4C25DA8EDFA Q39353122-4B705D47-1D67-449E-A675-B3D22F96313D Q39783472-1C69F005-B87A-4765-AB37-90CDA1BD6CB2 Q40383687-56C6FD2E-F2BB-4EED-AAF1-425486E3B30D Q40425878-AF06D19B-55D6-4DB7-B4D1-E7F689198605 Q40722978-A0C06C25-2085-420E-BB47-00C1F131041D Q46070749-AC26BA88-FF36-4A92-BB9C-B14EA707A106 Q47221249-E1E81E8B-0A81-453F-82C9-63CFDD5BC763 Q49109368-0A6CD45A-AB94-48CA-91E4-AFE59C730CCD Q49315243-A25407F3-58D7-4C93-96A1-FD47C763F3F3 Q49500732-3319B4B6-10C8-4C2C-B3EE-B10B753B6D11 Q50648388-A80D2F75-6CC9-4C46-B6B6-253A13130AB1 Q50759070-DE9A4334-0341-45BD-906B-5B0E1634F68E Q51353980-DA680351-65DF-4E00-8D57-C76ADCDF2353 Q51534305-135BFAB7-2C35-46AE-8B5E-077FB103246E

P2860

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

http://www.wikidata.org/entity/Q37445629

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

@en

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

@nl

type

label

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

@en

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

@nl

prefLabel

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

@en

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

@nl

P1433

Q37445629-9D202533-ECD6-4F4E-A3A3-461989F600C4

P1476

Q37445629-451D5CFF-D43D-41DF-9A8A-7A9099C9E542

P2093

Q37445629-230DC6D1-590C-4533-B3D3-042EA54981BF

Q37445629-56DDC633-ABD1-49F1-BF30-B2DA4A0F2918

Q37445629-5863168B-5C86-48C5-84BA-FB71E0495A62

Q37445629-725F45E3-2C2A-4232-BB7E-B10F6952FDE0

Q37445629-7C18645F-FB9F-4DFA-8445-E936283CE1E8

Q37445629-B2AC30CD-DE52-4235-8471-D4C79449B2F6

Q37445629-C5AADD44-5FCA-414B-ACBD-2DC197067046

Q37445629-CB2CCD52-FF65-444F-BE38-7752BECEF9DC

Q37445629-CB33DC17-564D-4890-94BC-74F08398792E

Q37445629-D7E08165-F047-424B-84CA-DA5F84DCB713

P2860

Q37445629-07A6529D-2B7C-4607-9175-095A18265000

Q37445629-0D7B2ACE-2B13-430E-AB3D-2B8AE9698683

Q37445629-164C1CF6-799A-4CC2-8F6C-86275E4E331F

Q37445629-1B43FBC8-2074-41B0-A989-BE8058736237

Q37445629-2B6A65D1-691B-4F79-BFC5-48967E9F3B00

Q37445629-3254CA0F-E6B4-4B05-98DC-DC424084E458

Q37445629-343BB7E6-85D7-4E6F-A8D7-57A4454794C5

Q37445629-4E5F6321-D46E-408A-B967-427061979449

Q37445629-52F77D5E-C3C9-4839-87AB-F05E0AC9E7FA

Q37445629-5A7E01D1-A184-46B1-B234-9E3B666EB02E

P304

Q37445629-3B7FB069-2B48-40C2-BE55-84966FB2E73D

P31

Q37445629-4C93B689-749B-4D9D-BEF2-636C6A3E97A9

P356

Q37445629-E5863383-A387-424E-ACC6-81C2F5021D62

P407

Q37445629-6C5EA7B9-7EB5-4120-91BC-69F3F06D3EFA

P433

Q37445629-0DB8F987-0B4C-47C4-B629-11A33F99F2D4

P478

Q37445629-26DC049C-7F83-403E-AC9C-FDA2E11A8354

P577

Q37445629-0C584456-239C-4783-AEDE-5066B59114CC

P698

Q37445629-4C62BC1B-CCE6-497D-B595-91340D9E444C

P921

Q37445629-2D7D8455-6CB3-4D6A-B8DB-A32BBC955549

Q37445629-611A8C76-AEEC-4D18-853E-587AB6AF7B69

P932

Q37445629-F1744EAB-04B4-41C6-909D-CF9E094BE9DE

P356

J.CGH.2013.06.010

P1433

Clinical Gastroenterology and Hepatology

P1476

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

@en

P2093

Colleen Brensinger

http://www.w3.org/2001/XMLSchema#string

Elizabeth Delzell

http://www.w3.org/2001/XMLSchema#string

Fenlong Xie

http://www.w3.org/2001/XMLSchema#string

James D Lewis

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Curtis

http://www.w3.org/2001/XMLSchema#string

Jie Zhang

http://www.w3.org/2001/XMLSchema#string

Kevin Haynes

http://www.w3.org/2001/XMLSchema#string

Lang Chen

http://www.w3.org/2001/XMLSchema#string

Mark T Osterman

http://www.w3.org/2001/XMLSchema#string

Meenakshi Bewtra

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Certolizumab pegol for the treatment of Crohn's disease

Infliximab for induction and maintenance therapy for ulcerative colitis

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding.

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Treatment continuation in patients receiving biological agents or conventional DMARD therapy.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

P304

811-817.e3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2013.06.010

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23811254

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

3883891

http://www.w3.org/2001/XMLSchema#string